Syros Pharmaceuticals (SYRS) Stock Forecast & Price Target

$1.95

+0.38 (+24.20%)

(As of 09/13/2024 ET)

Syros Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy
Based on 3 Analyst Ratings

Based on 3 Wall Street analysts who have issued ratings for Syros Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Buy." Out of the 3 analysts, 3 have given a buy rating for SYRS.

Consensus Price Target

$5.00
156.41% Upside

High Forecast	$6.00
Average Forecast	$5.00
Low Forecast	$4.00

According to the 3 analysts' twelve-month price targets for Syros Pharmaceuticals, the average price target is $5.00. The highest price target for SYRS is $6.00, while the lowest price target for SYRS is $4.00. The average price target represents a forecasted upside of 156.41% from the current price of $1.95.

Type	Current Forecast 9/16/23 to 9/15/24	1 Month Ago 8/17/23 to 8/16/24	3 Months Ago 6/18/23 to 6/17/24	1 Year Ago 9/16/22 to 9/16/23
Consensus Rating	Buy	Buy	Buy	Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	3 Buy rating(s)	3 Buy rating(s)	2 Buy rating(s)	4 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$5.00	$5.00	$14.00	$13.50
Forecasted Upside	156.41% Upside	24.58% Upside	173.44% Upside	271.26% Upside

Get Syros Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for SYRS and its competitors with MarketBeat's FREE daily newsletter.

Ad Porter & Company

War on Elon Escalates…

Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adoption of this technology for decades. By doing so he has put himself in the crosshairs of an ideological war with the global elites. And yet, while this new technology threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.

Click here to learn how you can benefit from its widespread distribution.

SYRS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

SYRS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Syros Pharmaceuticals Stock vs. The Competition

Type	Syros Pharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.77	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	156.41% Upside	1,061.03% Upside	8.61% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
8/13/2024	Piper Sandler 2 of 5 stars	Reiterated Rating	Overweight ➝ Overweight	$13.00 ➝ $5.00	+147.52%
8/13/2024	HC Wainwright 2 of 5 stars	Lower Target	Buy ➝ Buy	$15.00 ➝ $6.00	+19.76%
8/13/2024	JMP Securities 2 of 5 stars	Lower Target	Market Outperform ➝ Market Outperform	$12.00 ➝ $4.00	-20.16%
3/2/2023	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Outperform	$15.00 ➝ $13.00	+245.74%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 05:18 PM ET.

SYRS Forecast - Frequently Asked Questions

What is Syros Pharmaceuticals' forecast for 2024?: According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for Syros Pharmaceuticals is $5.00, with a high forecast of $6.00 and a low forecast of $4.00.
Should I buy or sell Syros Pharmaceuticals stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SYRS shares.
Does Syros Pharmaceuticals's stock price have much upside?: According to analysts, Syros Pharmaceuticals's stock has a predicted upside of 24.58% based on their 12-month stock forecasts.
What analysts cover Syros Pharmaceuticals?: Syros Pharmaceuticals has been rated by research analysts at HC Wainwright, JMP Securities, and Piper Sandler in the past 90 days.
Do Wall Street analysts like Syros Pharmaceuticals more than its competitors?: Analysts like Syros Pharmaceuticals more than other "medical" companies. The consensus rating for Syros Pharmaceuticals is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how SYRS compares to other companies.